S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
S&P 500   3,768.25
DOW   30,814.26
QQQ   311.86
Log in

Opthea Limited (OPT.AX) Stock Forecast, Price & News

Today's Range N/A
50-Day Range
MA: A$2.87
52-Week Range N/A
Volume504,572 shs
Average VolumeN/A
Market CapitalizationN/A
P/E RatioN/A
Dividend YieldN/A
Opthea Limited, a biotechnology company, develops and commercializes therapies primarily for eye disease in Australia. The company's development activities are based on the intellectual property portfolio covering Vascular Endothelial Growth Factors (VEGF) VEGF-C, VEGF-D, and VEGF Receptor-3 for the treatment of diseases associated with blood and lymphatic vessel growth, as well as vascular leakage. Its lead molecule is OPT-302, a soluble form of VEGFR-3 for the treatment of wet age-related macular degeneration and diabetic macular edema. The company was formerly known as Circadian Technologies Limited and changed its name to Opthea Limited in December 2015. Opthea Limited was incorporated in 1984 and is based in South Yarra, Australia.


Overall MarketRank

0.52 out of 5 stars

Analyst Opinion: 0.0Community Rank: 2.6Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -

Industry, Sector and Symbol

Industry Drug Manufacturers - Major
Phone61 3 9826 0399



Sales & Book Value

Annual Sales$149,575.00
Book ValueA$0.24 per share



Next Earnings DateN/A
OptionableNot Optionable

Receive OPT News and Ratings via Email

Sign-up to receive the latest news and ratings for OPT and its competitors with MarketBeat's FREE daily newsletter.

speech bubbles
speech bubbles

Opthea Limited (OPT.AX) (ASX:OPT) Frequently Asked Questions

What stocks does MarketBeat like better than Opthea Limited (OPT.AX)?

Wall Street analysts have given Opthea Limited (OPT.AX) a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but Opthea Limited (OPT.AX) wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were Opthea Limited (OPT.AX)'s earnings last quarter?

Opthea Limited (OPT.AX) (ASX:OPT) released its earnings results on Friday, August, 9th. The company reported ($0.09) EPS for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.00.
View Opthea Limited (OPT.AX)'s earnings history

Who are some of Opthea Limited (OPT.AX)'s key competitors?

What other stocks do shareholders of Opthea Limited (OPT.AX) own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Opthea Limited (OPT.AX) investors own include The Walt Disney (DIS), Datadog (DDOG), salesforce.com (CRM), (CGC), (BRK.B) (BRK.B), (AZN), American Water Works (AWK), Activision Blizzard (ATVI), Appian (APPN) and Advanced Micro Devices (AMD).

Who are Opthea Limited (OPT.AX)'s key executives?

Opthea Limited (OPT.AX)'s management team includes the following people:
  • Dr. Megan Baldwin M.A.I.C.D., Ph.D., MAICD, MD, CEO & Exec. Director (Age 46, Pay $591.3k)
  • Mr. Michael Tonroe B.Sc., F.C.A., M.A.I.C.D., Bsc(Hons), ACA, MAICD, CFO & Company Sec. (Age 54, Pay $351.56k)
  • Ms. Annie Lee, Fin. & Operations Mang.
  • Dr. Richard Chadwick, Head of Intellectual Property (Age 54)
  • Dr. Michael Gerometta, Head of Chemistry, Manufacturing & Controls Devel. (Age 56)
  • Dr. Ian Leitch, Director of Clinical Research (Age 57)
  • Dr. James Goding, Independent Consultant

What is Opthea Limited (OPT.AX)'s stock symbol?

Opthea Limited (OPT.AX) trades on the ASX under the ticker symbol "OPT."

How big of a company is Opthea Limited (OPT.AX)?

Opthea Limited (OPT.AX) has a market capitalization of $0.00 and generates $149,575.00 in revenue each year.

What is Opthea Limited (OPT.AX)'s official website?

The official website for Opthea Limited (OPT.AX) is www.opthea.com.

How can I contact Opthea Limited (OPT.AX)?

The company can be reached via phone at 61 3 9826 0399.

This page was last updated on 1/17/2021 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.